A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Different Doses of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Latest Information Update: 07 Nov 2023
Price :
$35 *
At a glance
- Drugs OPS 2071 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Otsuka Beijing Research Institute
- 30 Oct 2023 Status changed from not yet recruiting to recruiting.
- 30 Jun 2023 New trial record